Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has announced its participation in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City. The event will feature a fireside chat with David Moatazedi, President and CEO of Evolus, scheduled for Thursday, February 27, 2025, from 9:30 AM to 10:00 AM ET.
The fireside chat will be accessible via live webcast on the Investor Relations page of the Evolus website, with replay availability extending 90 days after the event.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has scheduled its fourth quarter and year end 2024 financial results announcement for Tuesday, March 4, 2025, after U.S. financial markets close.
The company will host a conference call and live webcast at 4:30 p.m. ET on the same day, featuring management presentations followed by a question-and-answer session. Participants can join via phone by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or through the live webcast on Evolus's Investor Relations webpage.
After the call, a replay will be available by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) using conference number 13751816. An archived webcast will also be accessible on the company's website.
Evolus (NASDAQ: EOLS) has received FDA approval for Evolysse™ Form and Evolysse™ Smooth, two injectable hyaluronic acid (HA) gels representing the first major technological breakthrough in dermal fillers in a decade. The company plans to launch these products in Q2 2025, expanding its addressable market by 78% to approximately $6 billion.
The products utilize innovative Cold-X™ technology designed to better preserve the HA molecule structure for long-lasting results. In clinical trials involving 140 patients, both products demonstrated statistical superiority compared to Restylane®-L. The company aims to achieve at least $700 million in net revenue and non-GAAP operating income margin of at least 20% by 2028.
Two additional products, Evolysse™ Sculpt and Evolysse™ Lips, are planned for launch in 2026 and 2027 respectively. The company also received EU MDR approval for four HA gels under the brand name Estyme®, with European launch planned for second half of 2025.
Evolus (NASDAQ: EOLS) has announced the approval of inducement grants for 34 newly hired non-executive employees. The compensation package includes 26,897 non-qualified stock options and 99,826 restricted stock units (RSUs). The stock options, priced at $13.11 per share, have a 10-year term and vest over 4 years, with 25% vesting annually. Similarly, the RSUs vest 25% each year over four years, starting February 7, 2025.
These grants were approved under Evolus' 2023 Inducement Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The awards are contingent upon continuous employment through each vesting date.
Evolus announced its preliminary unaudited net revenue for Q4 and full-year 2024, achieving record results. The company reported $79 million in net revenue for Q4 2024, a 30% increase over Q4 2023. For the full year 2024, Evolus reported $266.3 million in net revenue, representing a 32% increase over 2023 and at the top of its guidance range.
The company expects FDA approval within 90 days for its Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, with a U.S. launch planned for Q2 2025, ahead of schedule. Evolus projects 2025 net revenues of $345-$355 million, a 30-33% growth from 2024, with Evolysse™ and Estyme® HA gels contributing 8-10% of total revenue.
Non-GAAP operating expenses for 2025 are expected to be $230-$240 million, with profitability anticipated for the full year. The company continues to see strong performance from its Jeuveau® and Nuceiva® products, with Jeuveau® adding approximately 830 new accounts in Q4 2024 and a 70% reorder rate. The Evolus Rewards program saw a 40% increase in enrollment, ending 2024 with around 1.1 million consumers. As of December 31, 2024, Evolus had $87 million in cash and cash equivalents.
Evolus (NASDAQ: EOLS) has announced the grant of 15,332 restricted stock units (RSUs) to 6 newly hired non-executive employees. The grants were approved by the company's compensation committee under the 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of January 7, 2025. The RSUs will vest at a rate of 25% annually on each anniversary of the vesting commencement date. The grants serve as an inducement for employment and comply with Nasdaq Listing Rule 5635(c)(4). Recipients must maintain continuous employment to meet vesting requirements.
Evolus (NASDAQ: EOLS) has granted equity incentives to newly hired non-executive employees in November and December 2023. The November Grants include 9,872 stock options priced at $14.29 per share and 16,596 RSUs to 9 employees. The December Grants comprise 6,034 stock options at $12.66 per share and 22,295 RSUs to 11 employees. Both grants were approved under the company's 2023 Inducement Incentive Plan, with vesting dates set for November 7, 2024, and December 7, 2024, respectively. The stock options have a 10-year term with 25% annual vesting over 4 years, while RSUs vest 25% annually.
Evolus (NASDAQ: EOLS) reported Q3 2024 total net revenue of $61.1 million, up 22% from Q3 2023, with year-to-date growth of 33%. The company received EU approval for Estyme® Injectable Hyaluronic Acid Gels, with launch expected in H2 2025. Evolus narrowed its 2024 revenue guidance to $260-266 million, representing 29-32% year-over-year growth. The company added over 600 new customer accounts, reaching nearly 14,500 total customers with a 70% reorder rate. The Evolus Rewards™ program surpassed 1 million enrolled consumers. The company expects FDA approval and launch of Evolysse™ Form and Smooth by September 2025, projecting total net revenue of at least $700 million by 2028.
Evolus (NASDAQ: EOLS), a performance beauty company focused on aesthetics, has announced its upcoming participation in the Stifel Healthcare Conference. The company's management team will deliver a presentation in New York City on Tuesday, November 19 at 10:55 AM ET.
Interested parties can access the presentation through the Investor Relations section of the Evolus website. The webcast will remain available for replay for 90 days following the presentation date.
Evolus (NASDAQ: EOLS) has received EU Medical Device Regulation certification for four Estyme® injectable hyaluronic acid gels, marking its entry into the dermal filler segment. This certification doubles the company's addressable market outside the U.S. to $1.8 billion. The products, branded as Evolysse™ in the U.S., utilize proprietary cold technology and breakthrough cross-linking technology. Evolus plans a experience program with select physicians in Europe, followed by a broader launch in the second half of 2025. U.S. approval and launch of Evolysse™ remains on track for 2025.